Current:Home > FinanceModerna sues Pfizer over COVID-19 vaccine patents -Prime Capital Blueprint
Moderna sues Pfizer over COVID-19 vaccine patents
View
Date:2025-04-19 21:48:09
Vaccine maker Moderna announced Friday that it's suing rival drugmakers Pfizer and BioNtech for patent infringement. The lawsuit alleges the two companies used certain key features of technology Moderna developed to make their COVID-19 vaccine. It argues that Pfizer and BioNtech's vaccine infringes patents Moderna filed between 2010 and 2016 for its messenger RNA or mRNA technology.
All three companies' COVID-19 vaccines used mRNA technology which is a new way to make vaccines. In the past, vaccines were generally made using parts of a virus, or inactivated virus, to stimulate an immune response. With mRNA technology, the vaccine uses messenger RNA created in a lab to send genetic instructions that teach our cells to make a protein or part of a protein that triggers an immune response.
In October 2020, Moderna pledged not to enforce its COVID-19 related patents while the pandemic was ongoing, according to a statement from the company. In March this year, it said it will stick to its commitment not to enforce its COVID-19 related patents in low and middle-income countries, but expects rival companies like Pfizer to respect its intellectual property.
Moderna is not seeking to remove the Pfizer and BioNTech vaccine from the market, but is seeking monetary damages.
Moderna is filing the lawsuits against Pfizer and BioNTech in the U.S. District Court in Massachusetts and the Regional Court of Düsseldorf in Germany.
A Pfizer spokesperson said in a statement the company has not yet fully reviewed the complaint but it is "confident in our intellectual property supporting the Pfizer/BioNTech vaccine and will vigorously defend against the allegations of the lawsuit."
veryGood! (5411)
Related
- 'Squid Game' without subtitles? Duolingo, Netflix encourage fans to learn Korean
- Trump invites nearly all federal workers to quit now, get paid through September
- Arkansas State Police probe death of woman found after officer
- Highlights from Trump’s interview with Time magazine
- US wholesale inflation accelerated in November in sign that some price pressures remain elevated
- Highlights from Trump’s interview with Time magazine
- California DMV apologizes for license plate that some say mocks Oct. 7 attack on Israel
- 'Squid Game' without subtitles? Duolingo, Netflix encourage fans to learn Korean
- Trump's 'stop
- Trump issues order to ban transgender troops from serving openly in the military
Ranking
- How to watch new prequel series 'Dexter: Original Sin': Premiere date, cast, streaming
- Mets have visions of grandeur, and a dynasty, with Juan Soto as major catalyst
- This was the average Social Security benefit in 2004, and here's what it is now
- Tarte Shape Tape Concealer Sells Once Every 4 Seconds: Get 50% Off Before It's Gone
- Federal hiring is about to get the Trump treatment
- Military service academies see drop in reported sexual assaults after alarming surge
- The Grammy nominee you need to hear: Esperanza Spalding
- IRS recovers $4.7 billion in back taxes and braces for cuts with Trump and GOP in power
Recommendation
McKinsey to pay $650 million after advising opioid maker on how to 'turbocharge' sales
B.A. Parker is learning the banjo
Dick Vitale announces he is cancer free: 'Santa Claus came early'
Are Instagram, Facebook and WhatsApp down? Meta says most issues resolved after outages
North Carolina justices rule for restaurants in COVID
All That You Wanted to Know About She’s All That
At site of suspected mass killings, Syrians recall horrors, hope for answers
McKinsey to pay $650 million after advising opioid maker on how to 'turbocharge' sales